Overview

Aftovaxpur DOE has been withdrawn at the request of the marketing authorisation holder.

español (ES) (172.3 KB - PDF)

View

eesti keel (ET) (162.94 KB - PDF)

View

français (FR) (174.49 KB - PDF)

View

hrvatski (HR) (200.82 KB - PDF)

View

italiano (IT) (165.88 KB - PDF)

View

latviešu valoda (LV) (218.99 KB - PDF)

View

lietuvių kalba (LT) (217.75 KB - PDF)

View

magyar (HU) (202.82 KB - PDF)

View

Malti (MT) (228.87 KB - PDF)

View

Nederlands (NL) (175.04 KB - PDF)

View

polski (PL) (219.81 KB - PDF)

View

português (PT) (173.64 KB - PDF)

View

română (RO) (214.89 KB - PDF)

View

slovenčina (SK) (223.99 KB - PDF)

View

slovenščina (SL) (199.83 KB - PDF)

View

Suomi (FI) (166.62 KB - PDF)

View

svenska (SV) (170.28 KB - PDF)

View

Product information

български (BG) (886.49 KB - PDF)

View

español (ES) (582.68 KB - PDF)

View

čeština (CS) (660.11 KB - PDF)

View

dansk (DA) (561.16 KB - PDF)

View

Deutsch (DE) (590.71 KB - PDF)

View

eesti keel (ET) (590.49 KB - PDF)

View

ελληνικά (EL) (884.66 KB - PDF)

View

français (FR) (592.03 KB - PDF)

View

hrvatski (HR) (654.4 KB - PDF)

View

íslenska (IS) (543.52 KB - PDF)

View

italiano (IT) (599.14 KB - PDF)

View

latviešu valoda (LV) (734.82 KB - PDF)

View

lietuvių kalba (LT) (722.56 KB - PDF)

View

magyar (HU) (663.56 KB - PDF)

View

Malti (MT) (740.29 KB - PDF)

View

Nederlands (NL) (561.3 KB - PDF)

View

norsk (NO) (538.94 KB - PDF)

View

polski (PL) (771.72 KB - PDF)

View

português (PT) (554.32 KB - PDF)

View

română (RO) (725.86 KB - PDF)

View

slovenčina (SK) (702.49 KB - PDF)

View

slovenščina (SL) (662.49 KB - PDF)

View

Suomi (FI) (551.34 KB - PDF)

View

svenska (SV) (532.56 KB - PDF)

View

Latest procedure affecting product information: IG/1204/G

20/03/2020

български (BG) (807.49 KB - PDF)

View

español (ES) (1.28 MB - PDF)

View

čeština (CS) (645.24 KB - PDF)

View

dansk (DA) (627.43 KB - PDF)

View

Deutsch (DE) (685.67 KB - PDF)

View

eesti keel (ET) (668.12 KB - PDF)

View

ελληνικά (EL) (647.06 KB - PDF)

View

français (FR) (748.55 KB - PDF)

View

hrvatski (HR) (642.38 KB - PDF)

View

íslenska (IS) (693.42 KB - PDF)

View

italiano (IT) (713.91 KB - PDF)

View

latviešu valoda (LV) (714.86 KB - PDF)

View

lietuvių kalba (LT) (615.74 KB - PDF)

View

magyar (HU) (661.6 KB - PDF)

View

Malti (MT) (779.85 KB - PDF)

View

Nederlands (NL) (669.1 KB - PDF)

View

norsk (NO) (706.57 KB - PDF)

View

polski (PL) (598.16 KB - PDF)

View

português (PT) (718.68 KB - PDF)

View

română (RO) (704.33 KB - PDF)

View

slovenčina (SK) (644.86 KB - PDF)

View

slovenščina (SL) (645.07 KB - PDF)

View

Suomi (FI) (639.14 KB - PDF)

View

svenska (SV) (647.06 KB - PDF)

View

Product details

Name of medicine
Aftovaxpur DOE
Active substance
Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063.
International non-proprietary name (INN) or common name
inactivated vaccine against foot-and-mouth disease
Species
  • Pigs
  • Cattle
  • Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA04

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.

Authorisation details

EMA product number
EMEA/V/C/002292
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein
Germany

Marketing authorisation issued
15/07/2013
Revision
8

Assessment history

Topics

This page was last updated on

How useful do you find this page?